The number of copies of the DEFA1A3 gene — which encodes antimicrobial defensin peptides — directly determines how well the kidney fights off E. coli urinary tract infections in a dose-dependent manner.
Gene dose-dependent protectionMice with more copies of the human DEFA1A3 gene produced more alpha-defensin peptides and showed stronger antimicrobial and immune responses against urinary tract E. coli infection.
What the researchers found
Using transgenic mice carrying the human DEFA1A3 gene, researchers demonstrated that alpha-defensin 1-3 expression and antimicrobial activity against uropathogenic E. coli (UPEC) are directly dependent on gene copy number — more copies mean stronger defense.
Alpha-defensin 1-3 was expressed by both kidney neutrophils and collecting duct intercalated cells, establishing two sources of this antimicrobial peptide in the urinary tract. The defensins showed cooperative effects with other antimicrobial peptides, potentiating their bacteria-killing activity. Higher gene dosage also modulated pro-inflammatory innate immune responses, demonstrating that DEFA1A3 has both direct antimicrobial and immunomodulatory roles during UTI.
Why it matters
Urinary tract infections are among the most common bacterial infections, especially in children, and antibiotic resistance is a growing concern. Understanding that a patient's genetic copy number of defensin genes directly influences their susceptibility to UTIs could lead to personalized risk assessment and potentially new therapeutic strategies that boost natural antimicrobial peptide defenses rather than relying solely on antibiotics.
How the study worked
The researchers used a previously characterized transgenic mouse model carrying knock-in copies of the human DEFA1A3 gene at different copy numbers. Mice were infected with uropathogenic E. coli to induce upper urinary tract infection. The team measured alpha-defensin expression in kidney tissue (from neutrophils and collecting duct intercalated cells), assessed bacterial killing activity, evaluated cooperative effects between alpha-defensins and other antimicrobial peptides, and characterized innate immune responses as a function of gene dosage.
What this study cannot tell us
The study used a transgenic mouse model, which may not perfectly replicate human kidney physiology and immune responses. The exact copy-number thresholds that affect clinical UTI outcomes in humans remain to be defined. The study focused on E. coli UTI specifically; results may differ for other uropathogens. The relative contribution of neutrophil-derived versus intercalated cell-derived defensins to overall protection was not fully quantified.
How to read the evidence
This is a well-designed preclinical study using a humanized transgenic mouse model with clear mechanistic findings. While the transgenic approach provides good translational relevance, the results still require validation in human clinical studies to confirm the relationship between DEFA1A3 copy number and UTI susceptibility.
When this study was published
Published in 2024, this is a very recent study representing current research into antimicrobial peptide genetics and innate immunity. The DEFA1A3 copy-number variation field continues to develop rapidly.
The bigger picture
This study contributes to the growing understanding that genetic variation in antimicrobial peptide genes — not just immune cell counts or antibody levels — plays a crucial role in infectious disease susceptibility. Copy-number variation is an underappreciated source of genetic diversity in immune defense. As antimicrobial resistance rises, harnessing the body's natural peptide-based defenses becomes increasingly important as a complementary strategy to conventional antibiotics.
Questions still open
- Could DEFA1A3 copy-number testing be used clinically to identify children at higher risk for recurrent UTIs?
- Is it possible to therapeutically supplement alpha-defensin levels in patients with low copy numbers to prevent UTIs?
- Do DEFA1A3 copy-number variations similarly affect susceptibility to other types of infections beyond the urinary tract?
Common questions
What are alpha-defensins and how do they fight infections?
Why do some children get more urinary tract infections than others?
Read the original research
DEFA1A3 DNA gene-dosage regulates the kidney innate immune response during upper urinary tract infection.
Life science alliance, 7(6)
Citation
Canas, Jorge J; Arregui, Samuel W; Zhang, Shaobo; Knox, Taylor; Calvert, Christi; Saxena, Vijay; Schwaderer, Andrew L; Hains, David S. (2024). DEFA1A3 DNA gene-dosage regulates the kidney innate immune response during upper urinary tract infection.. Life science alliance, 7(6). https://doi.org/10.26508/lsa.202302462